<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118999</url>
  </required_header>
  <id_info>
    <org_study_id>16.18.BIO</org_study_id>
    <nct_id>NCT03118999</nct_id>
  </id_info>
  <brief_title>Plasma Level of Various Omega-3 Lipids</brief_title>
  <official_title>Plasma Level of Various Omega-3 Lipids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetic properties of 3 OM3&#xD;
      oils after a single-dose administration in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open design, randomized, controlled, cross-over trial with 3 test&#xD;
      periods and 3 products (one test period per product). The three different test periods will&#xD;
      be separated by a washout period of at least 6 days (up to 21 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">April 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single center, open design, randomized, controlled, cross-over trial with 3 test periods and 3 food supplements containing omega3 (one test period per product).</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-24h) Plasma OM3</measure>
    <time_frame>From Time 0 hour to Time 24 hours</time_frame>
    <description>Baseline-adjusted total plasma OM3 AUC(0-24h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (AUC) for EPA and DHA</measure>
    <time_frame>From Time 0 hour to Time 24 hours</time_frame>
    <description>AUC(0-24h) Plasma EPA and DHA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (Cmax) for EPA and DHA</measure>
    <time_frame>From Time 0 hour to Time 24 hours</time_frame>
    <description>Cmax Plasma EPA and DHA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (Tmax) for EPA and DHA</measure>
    <time_frame>From Time 0 hour to Time 24 hours</time_frame>
    <description>Tmax Plasma EPA and DHA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>OM3-FFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega3 linked to free fatty acids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OM3 -MAG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega3 linked to Monoacylglycerol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OM3-EE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega3 linked to ethylester</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OM3-FFA</intervention_name>
    <description>Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design</description>
    <arm_group_label>OM3 -MAG</arm_group_label>
    <arm_group_label>OM3-EE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OM3-MAG</intervention_name>
    <description>Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design</description>
    <arm_group_label>OM3-EE</arm_group_label>
    <arm_group_label>OM3-FFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OM3-EE</intervention_name>
    <description>Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design</description>
    <arm_group_label>OM3 -MAG</arm_group_label>
    <arm_group_label>OM3-FFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 18 and 65 years old&#xD;
&#xD;
          -  BMI in the normal and overweight range (18.5 to 29.9 kg/m2)&#xD;
&#xD;
          -  Able to understand and to sign written informed consent prior to trial entry&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Food allergy&#xD;
&#xD;
          -  Documented clinically relevant disease impacting the endpoints of the study or the&#xD;
             safety of the subject, as determined by the medical (screening) visit:&#xD;
&#xD;
             i. Malabsorptive disorders including but not limited to pancreatitis, Crohn's disease,&#xD;
             etc. ii. Known hypertriglyceridemia (on anamnesis) iii. Known Type2 Diabetes Mellitus&#xD;
&#xD;
          -  Under medication that may impact:&#xD;
&#xD;
               1. Dietary fat absorption and metabolism like statins, bile acid sequestrants, lipid&#xD;
                  lowering medications, or fibrates (to the opinion of the investigator)&#xD;
&#xD;
               2. Coagulation (blood thinning medications, anticoagulants). Indeed, OM3 have been&#xD;
                  shown to possibly exert some bleeding by themselves that may increase the&#xD;
                  bleeding effects of aspirin and anticoagulants&#xD;
&#xD;
          -  Having taken omega-3, EPA/DHA, fish oil supplementation for more than two consecutive&#xD;
             weeks during the last 2 months&#xD;
&#xD;
          -  Having given blood within the last month, or willing to make a blood donation until&#xD;
             one month following the end of the study&#xD;
&#xD;
          -  Subjects not willing and/or not able to comply with scheduled visits and with the&#xD;
             requirements of the study protocol, including trial products consumption and food&#xD;
             restriction&#xD;
&#xD;
          -  Pregnancy (on anamnesis)&#xD;
&#xD;
          -  Any direct collaborator of the study leader (Dr. Maurice Beaumont)&#xD;
&#xD;
          -  Currently participating or having participated in another clinical trial during the&#xD;
             last month prior to the beginning of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Cuénoud</last_name>
    <role>Study Director</role>
    <affiliation>Nestec Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nestlé Research Center / Clinical Development Unit / Metabolic Unit</name>
      <address>
        <city>Lausanne 26</city>
        <state>Vaud</state>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

